Shares of Seres Therapeutics Inc (NASDAQ:MCRB) have earned a consensus rating of “Buy” from the eight research firms that are covering the firm. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $25.00.
A number of research firms have issued reports on MCRB. FBR & Co restated an “outperform” rating and issued a $18.00 target price on shares of Seres Therapeutics in a report on Monday, March 20th. Cantor Fitzgerald set a $16.00 target price on shares of Seres Therapeutics and gave the company a “buy” rating in a report on Tuesday, January 31st. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, February 1st. Zacks Investment Research lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 2nd. Finally, Canaccord Genuity restated a “buy” rating and issued a $20.00 target price on shares of Seres Therapeutics in a report on Tuesday, January 31st.
COPYRIGHT VIOLATION NOTICE: “Brokerages Set Seres Therapeutics Inc (MCRB) Price Target at $25.00” was originally published by sleekmoney and is owned by of sleekmoney. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at http://sleekmoney.com/brokerages-set-seres-therapeutics-inc-mcrb-price-target-at-25-00/1739430.html.
Shares of Seres Therapeutics (NASDAQ:MCRB) traded down 0.28% on Monday, hitting $10.62. 175,908 shares of the company were exchanged. The company has a 50-day moving average price of $10.40 and a 200 day moving average price of $10.64. The firm’s market cap is $428.71 million. Seres Therapeutics has a 52-week low of $8.05 and a 52-week high of $35.98.
Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Thursday, March 16th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.07. The firm earned $3 million during the quarter, compared to analysts’ expectations of $3 million. The business’s revenue for the quarter was up NaN% on a year-over-year basis. Analysts predict that Seres Therapeutics will post ($2.75) EPS for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can raised its position in Seres Therapeutics by 33.7% in the first quarter. Bank of Montreal Can now owns 19,144 shares of the company’s stock worth $216,000 after buying an additional 4,829 shares during the period. JPMorgan Chase & Co. raised its position in shares of Seres Therapeutics by 2.8% in the third quarter. JPMorgan Chase & Co. now owns 218,589 shares of the company’s stock valued at $2,687,000 after buying an additional 5,972 shares during the last quarter. Ellington Management Group LLC bought a new position in shares of Seres Therapeutics during the fourth quarter valued at $107,000. Teachers Advisors LLC raised its position in shares of Seres Therapeutics by 43.5% in the fourth quarter. Teachers Advisors LLC now owns 41,101 shares of the company’s stock valued at $407,000 after buying an additional 12,462 shares during the last quarter. Finally, Trexquant Investment LP raised its position in shares of Seres Therapeutics by 147.5% in the fourth quarter. Trexquant Investment LP now owns 25,924 shares of the company’s stock valued at $257,000 after buying an additional 15,450 shares during the last quarter. Institutional investors own 77.62% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/brokerages-set-seres-therapeutics-inc-mcrb-price-target-at-25-00/1739430.html
Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.